| Anixa Biosciences is a biotechnology company developing therapies and vaccines that are focused on unmet needs in oncology and infectious disease. Co.'s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell technology, initially focused on treating ovarian cancer and the discovery and development of anti-viral drug candidates for the treatment of Coronavirus disease 2019 focused on inhibiting certain protein functions of the virus. Co.'s vaccine programs include the development of a vaccine against triple negative breast cancer as well other forms of breast cancer and a vaccine against ovarian cancer. We show 16 historical shares outstanding datapoints in our ANIX shares outstanding history coverage, used to compute ANIX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANIX market cap history over the course of time is important for investors
interested in comparing ANIX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANIX versus a peer is one thing; comparing
ANIX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANIX can fluctuate over the course of history.
With this page we aim to empower investors researching ANIX by allowing them to research the ANIX market cap history.